332
Participants
Start Date
November 10, 2021
Primary Completion Date
July 1, 2027
Study Completion Date
July 1, 2027
Ursodeoxycholic Acid
Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
Placebo
Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
NOT_YET_RECRUITING
Hospital Clínico Universitario de Santiago, Santiago de Compostela
NOT_YET_RECRUITING
Hospital Clínio San Cecilio, Granada
RECRUITING
Hospital Costa del Sol,, Marbella
RECRUITING
Clinica Unversidad de Navarra, Pamplona
NOT_YET_RECRUITING
Complejo Hospitalario de Ourense, Ourense
RECRUITING
Hospital Universitario Central de Asturias., Oviedo
NOT_YET_RECRUITING
Hospital Universitario Marqués de Valdecilla, Santander
RECRUITING
Hospital Clínico Universitario de Valencia, Alicante
RECRUITING
Hospital Clínico Universitario de Valladolid, Valladolid
RECRUITING
Hospital Universitario de Cruces, Bilbao
RECRUITING
Hospital Clínico Lozano Blesa, Zaragoza
NOT_YET_RECRUITING
Hospital Universitario Miguel Servet, Zaragoza
RECRUITING
Hospital General Universitario de Alicante, Alicante
NOT_YET_RECRUITING
Hospital General Universitario de Elche, Elche
NOT_YET_RECRUITING
Hospital Univerisitario Vall D´Hebron, Barcelona
NOT_YET_RECRUITING
Hospital de Bellvitge, L'Hospitalet de Llobregat
NOT_YET_RECRUITING
Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell
RECRUITING
Hospital Ramon y Cajal, Madrid
Instituto de Salud Carlos III
OTHER_GOV
Hospital General Universitario de Alicante
OTHER